Abstract
We used multi-agent simulations to estimate the testing capacity required to find and isolate a number of infections sufficient to break the chain of transmission of SARS-CoV-2. Depending on the mitigation policies in place, a daily capacity between 0.7 to 3.6 tests per thousand was required to contain the disease. However, if contact tracing and testing efficacy dropped below 60% (e.g. due to false negatives or reduced tracing capability), the number of infections kept growing exponentially, irrespective of any testing capacity. Under these conditions, the population’s geographical distribution and travel behaviour could inform sampling policies to aid a successful containment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
XG is supported by National Institute on Drug Abuse [grant numbers: R01DA043695, R21DA049243], National Institute of Mental Health [R21MH120789], The Swartz Foundation, and The Realm Foundation. NDF is supported by National Aeronautics and Space Administration [ECOSTRES18-0046], National Institute Environmental health sciences [R24ES028522, UH3OD023337]. DC is supported by the National Research Foundation of Korea [NRF-2018R1D1A1B07043582]. The funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study presents simulated data. No IRB was required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Simulated data are available upon request.
